Last $0.45 USD
Change Today +0.0025 / 0.56%
Volume 258.7K
ONCS On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

oncosec medical inc (ONCS) Snapshot

Open
$0.44
Previous Close
$0.45
Day High
$0.46
Day Low
$0.44
52 Week High
03/5/14 - $0.97
52 Week Low
08/5/14 - $0.36
Market Cap
111.6M
Average Volume 10 Days
867.6K
EPS TTM
$-0.07
Shares Outstanding
246.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOSEC MEDICAL INC (ONCS)

Related News

No related news articles were found.

oncosec medical inc (ONCS) Related Businessweek News

No Related Businessweek News Found

oncosec medical inc (ONCS) Details

OncoSec Medical Incorporated, a hybrid device and gene therapy biotechnology company, designs, develops, and commercializes medical approaches principally immunotherapy for the treatment of solid tumors in the United States. Its clinical programs include three Phase II clinical trials to assess the ImmunoPulse technology in patients with melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated is headquartered in San Diego, California.

42 Employees
Last Reported Date: 10/10/14

oncosec medical inc (ONCS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $467.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $310.0K
Chief Scientific Officer and Global Head of R...
Total Annual Compensation: $172.8K
Compensation as of Fiscal Year 2014.

oncosec medical inc (ONCS) Key Developments

Oncosec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulse

OncoSec Medical Inc. has initiated a Phase II trial in squamous cell carcinoma of the head and neck (SCCHN) using its proprietary ImmunoPulse platform. The multicenter study is scheduled to be initiated in the first quarter of 2015, with the University of California San Francisco, under the direction of Dr. Alain Algazi as the first site of enrollment. The study will enroll patients with treatment-refractory metastatic and unresectable SCCHN, regardless of HPV status. Eligible patients will receive up to nine cycles of IL-12 ImmunoPulse at six-week intervals and will be followed for clinical response and safety. The first stage of the study will enroll 20 patients with measurable disease. If three or more objective responses are observed, an additional 11 patients with measurable disease will be treated, for a total of 31 patients. The primary endpoint for this study will be best overall response by RECIST 1.1.

Oncosec Medical Inc. Announces Earnings Results for the First Quarter Ended October 31, 2014

OncoSec Medical Inc. announced earnings results for the first quarter ended October 31, 2014. For the quarter, the company reported a net loss of $4.1 million, or $0.02 per share, compared to a net loss of $2.1 million, or $0.01 per share, for the same period last year. There were no revenues for quarter ended October 31, 2014 or October 31, 2013.

OncoSec Medical Incorporated - Special Call

To consider recent milestone achievements and corporate and clinical development strategies, but will not address the company's results of operations or financial condition for a completed quarterly or annual fiscal period

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $0.45 USD +0.0025

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies
 

Industry Analysis

ONCS

Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOSEC MEDICAL INC, please visit www.oncosec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.